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Abstract
Background: Common mental disorders (CMDs) are highly prevalent and contribute significantly to the global
burden of disease, yet there is evidence of a large treatment gap. We aimed to quantify this gap among young
adults with symptoms of CMDs and examine the relationship between substance use and perceived need for care
and mental health service utilization.
Methods: In a nationally representative, cross-sectional survey of young Swiss adults’ mental health and wellbeing,
we assessed symptoms of anxiety, depression, and attention deficit hyperactivity disorder (ADHD) with widely used
screening instruments and asked about participant suicidal ideation, suicide attempts, mental health-related quality
of life, alcohol and drug use, perceived need for mental health care, and mental health service utilization. We used
these variables to calculate the treatment gap and weighted all analyses according to the stratified sampling plan.
Results: Around a quarter of young adults screened positive for at least one CMD. Participants who screened
positive for anxiety and/or depression reported significantly more suicidal ideation and lifetime suicide attempts
and reported worse mental health-related quality of life than participants who did not screen positive for a
disorder. Women’s prevalence of anxiety and depression symptoms was significantly higher than men’s, while men
were more likely to report most types of risky drug use. Among those with a CMD, only around half perceived
lifetime need for care, and less than 20% reported currently utilizing mental health services. Young adults with a
CMD reporting risky weekly use of alcohol were less likely to be currently using services.
Conclusion: The high prevalence of CMD symptoms could reflect a rising prevalence of these disorders mirroring
increasing trends observed in other countries. To address the large treatment gap, interventions promoting mental
health literacy and more research on additional barriers to inform further interventions are needed.
Keywords: Adolescents, Young adult, Mental disorders, Anxiety disorders, Depression, Attention deficit hyperactivity
disorder, Alcohol consumption, Drug utilization, Mental health services, Service utilization
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: m.mohler-kuo@ecolelasource.ch
1La Source, School of Nursing Sciences, HES-SO University of Applied
Sciences and Arts of Western Switzerland, Lausanne, Switzerland
2Department of Child and Adolescent, Psychiatry and Psychotherapy,
University Hospital of Psychiatry Zurich, University of Zurich, Zurich,
Switzerland
Full list of author information is available at the end of the article
Werlen et al. BMC Public Health         (2020) 20:1470 
https://doi.org/10.1186/s12889-020-09577-6
Background
Throughout the world, common mental disorders (CMDs),
which include anxiety-related and depressive disorders [1],
are highly prevalent. An estimated 4.4% of the world’s popu-
lation suffers from depression alone in a given year [1]. In
addition, CMDs constitute one of the leading causes of
disability-adjusted life years (DALYs) [2], and CMDs’ global
burden continues to grow over time [3]: by 2030, depression
is predicted to become the leading cause of disability in
high-income countries [4]. Though the onset of mental dis-
orders varies, most typically have their onset in late adoles-
cence [5], and the burden of these illnesses is especially high
for young people [3]. In Switzerland, the burden and costs
are also significant; the accompanying total economic costs
have been estimated at 3.5% of GDP [6].
Despite the significant impact of CMDs, there is evidence
that many people suffering from such disorders are never
diagnosed or do not access timely and/or appropriate treat-
ment; across the world, this treatment gap has been esti-
mated at over 50%, meaning that more than half of the
people who could benefit from services do not reach them
[7, 8]. Even among severe cases of mental disorders, only
around half ever receive mental health treatment [9].
Expanding beyond estimates of prevalence and service
utilization by quantifying and assessing the treatment
gap is important in order to better understand who is
not reaching services and why. In addition, the conse-
quences of not receiving professional care need to be
measured, including potential self-medication through
the risky use of alcohol and drugs [10]. Previous research
on factors impacting service utilization shows that bar-
riers are wide-ranging, from individual behaviors to so-
cial norms to environmental factors [11, 12]. Young
adults face specific obstacles related to their stage of life
(e.g., limited financial resources, unfamiliarity with the
health care system, fear of judgment from family, peers,
or employers) [10, 13]. Certain sub-groups of the popu-
lation, such as people of low socio-encomic status or
ethnic minorities, must contend with even more barriers
[12].
Despite the dimensions and importance of the burden
of CMDs on young adults, there are hardly any epi-
demiological data on the prevalence of mental disorders,
service utilization, and therefore the treatment gap in
Switzerland as yet, and this is especially the case for
young people [14]. In the context of international trends
indicating the growing burden and increased prevalence
of CMDs [15, 16], we aimed to estimate the prevalence
of the CMDs depression and anxiety as well as ADHD
(another one of the most prevalent disorders in adoles-
cence and young adulthood [17–19]), risky substance use
and the prevalence of perceived need for treatment, life-
time and current service utilization, and the treatment
gap between those in need of professional health services
and those who receive them among those diagnosed
using a representative sample of young adults in
Switzerland. To explore possible causes of the treatment
gap, we also analyzed whether participants with CMDs





We used data from the Swiss Youth Epidemiological
Study on Mental Health (S-YESMH), a nationally repre-
sentative, cross-sectional study of Swiss young adults’
mental health and wellbeing that was funded by the
Swiss National Science Foundation and approved by the
Ethics Committee of the Canton of Vaud (2017–00522).
In order to obtain answers from participants of both
Swiss and Non-Swiss nationality from all states (can-
tons), we developed a sampling plan stratified by canton,
sex, and Swiss nationality that oversampled Non-Swiss
participants, for which we adjusted in our statistical ana-
lyses. Based on this plan, the Swiss Federal Statistical Of-
fice provided us a random sample of 9805 young adults
legally residing in Switzerland born between 1996 and
2000 (17–21 years old on December 31, 2017) who were
randomly selected from the population register within
each stratum specified by the sampling plan. Participants
who were not able to complete the survey in German,
French, or Italian were excluded from the survey. From
the 9286 valid addresses in the sample at the time of
data collection, 3840 participants (41.4%) completed the
online survey.
Procedure
The data were collected via a cross-sectional online sur-
vey from February to August 2018 by the market re-
search organization LINK Institute (www.link.ch). We
sent an invitation letter by postal mail to every person
sampled. This letter described the study, stated that the
survey was voluntary and that answers would never be
linked to participant contact information, and provided
free hotline numbers for participants to contact the
study team, LINK Institute, or mental health organiza-
tions if they had additional questions about the study or
mental health in general. Participants could access the
survey by entering the web address and password pro-
vided or by scanning an individualized QR code on the
invitation letter. The survey duration was around 25 min
and included questions on socio-demographic character-
istics, symptoms of several common psychological disor-
ders and suicide, somatic symptoms, service use, quality
of life, sources of stress, social support, and alcohol and
drug use. After three weeks, a first reminder letter was
sent to participants who had not responded to the
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survey. Two weeks after this, LINK Institute called those
who had not participated to encourage them to partici-
pate. Those who provided their e-mail address during
the telephone call, but had not filled out the survey, were
reminded to participate by e-mail. We sent a second re-
minder letter that included an optional paper version of
the questionnaire one month after the telephone re-
minders began. Finally, we sent a last reminder letter
four months after sending the initial invitation letter.
Measures
Symptoms of common mental disorders (CMDs)
The common mental disorders in focus in this study were
depression, anxiety, and attention deficit hyperactivity dis-
order (ADHD). Two Patient Health Questionnaire (PHQ)
screeners were used to assess symptoms of CMDs: the
Generalized Anxiety Disorder 7 (GAD-7) for anxiety [20]
and the PHQ-9 for depression [21]. Both are widely used
in clinical settings and have been validated in populations
across the world [22–24] (note: though the German,
French, and Italian versions have been validated, they have
not all been validated in Switzerland specifically). For the
PHQ-9, sensitivity is 80% and specificity is 92%, while the
sensitivity of the GAD-7 is 89% and its specificity is 82%
[23]. In this study, Cronbach’s alpha was 0.85 for the
PHQ-9 and 0.87 for the GAD-7. These screeners ask
about symptoms of anxiety and depression, respectively,
over the past two weeks using a four-point rating scale for
which 0 indicates ‘not at all’ and 3 indicates ‘always’. Based
on the literature, we dichotomized total scores for these
screeners into moderate anxiety and above (scores greater
than or equal to 10) and moderate depression and above
(scores greater than or equal to 10) [23]. ADHD symp-
toms were assessed using the Adult ADHD Self-Report
Scale Screener (ASRS-v1.1), a validated six-item instru-
ment about symptoms of ADHD during the past 6 months
[25–27]. This instrument has adequate sensitivity (68.7%)
and is highly specific (99.5%) [25]. Cronbach’s alpha was
0.6 in this study. We dichotomized total scores into ‘no
ADHD’ (scores below 14) and ‘ADHD’ (scores 14–24)
[28]. We also created a variable ‘anxiety, depression, or
ADHD’ that included any participant who screened posi-
tive for at least one of these disorders.
Because the instruments used to measure CMDs assessed
self-reported symptoms, we do not have sufficient informa-
tion to establish a formal clinical diagnosis. In this study,
we thus refer to people who report symptoms of the
CMDs under study and probably suffer from them.
Risky substance use
We assessed risky alcohol and substance use with ques-
tions about the usual quantity and frequency of sub-
stance consumption using the questionnaire from the
Cohort Study on Substance Use Risk Factors (C-SURF),
a study of young men in Switzerland [29, 30]. Risky alco-
hol use was defined as the frequency of risky single-
occasion drinking over the last 12 months. For men,
risky single-occasion drinking meant consuming at least
six standard drinks on a single occasion, and for women,
four standard drinks (the definition of a standard drink
was clarified using pictures with examples). We calcu-
lated two dichotomous variables for risky alcohol use:
risky alcohol use at least monthly and risky alcohol use
at least weekly based on the frequency of risky single-
occasion drinking in each time period. Risky drug use
was calculated for different classes of illicit substances.
Risky cannabis use was defined as using cannabis at least
2–3 times per week; risky use of non-prescribed pre-
scription drugs was defined as using prescription drugs
not prescribed by a doctor at least two to three times
per year; and risky illicit drug use was defined as using
any other illicit drug at least four times throughout the
participant’s lifetime.
Other mental health outcomes
Current suicidal ideation was measured using the question
from the PHQ-9 “How often have you been bothered by
thoughts that you would be better off dead or of hurting
yourself in some way over the last two weeks?” Answers
were dichotomized into no suicidal ideation (answer
choice “not at all”) and suicidal ideation (combined answer
choices “several days,” “more than half the days,” and
“nearly every day”). We assessed lifetime suicide attempts
using the question from the Swiss Health Survey 2017
“Have you ever attempted to take your life?” [31].
Mental health-related quality of life was measured using
the Short-Form 12 Health Survey, Version 2 (SF-12) [32].
We calculated the Mental Component Summary score
following the standard procedure using norm-based
methods described in the SF-12 user manual. A score of
50 represents the average for the U.S. population in 1998,
with higher scores indicating better quality of life.
Perceived need for and utilization of mental health care
services
Questions on perceived need for health and mental
health care service utilization were assessed using ques-
tions modified from the World Health Organization
World Mental Health Composite International Diagnos-
tic Interview (WHO WMH-CIDI) [33]. Lifetime per-
ceived need for health care services was assessed by the
yes/no question “Has there ever been a time in your life
that you believe you required help for problems with
your emotions, nerves, mental health, or your use of al-
cohol or drugs?” Lifetime mental health care service
utilization was assessed by asking whether the partici-
pant had ever spoken with a health professional (i.e.,
psychiatrist, general practitioner, nurse, psychologist,
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care personnel, or counselor) in person or on the phone
for problems with emotions, nerves, or use of alcohol or
drugs. For current mental health care service utilization,
we asked the same question for the period including the
last four weeks.
Treatment gap
To measure the treatment gap, we first identified those
who screened positive for CMDs and then measured
their use of mental health care services by asking those
who reported a perceived lifetime need for mental health
care services a yes/no question about whether this need
had been met. In addition, we looked at the percentage
of participants who met the criteria for a disorder, yet
had not used health care services either in the last four
weeks or at any point during their lifetime.
Service availability
Service availability was represented by the regional
psychiatrist density, which we defined as the number of
psychiatrists per 100,000 inhabitants in the seven large
Nomenclature of Territorial Units for Statistics 2
(NUTS-2) regions defined by the Swiss Federal Statis-
tical Office (i.e., Lake Geneva region, Espace Mittelland,
Northwestern Switzerland, Zurich, Eastern Switzerland,
Central Switzerland, and Ticino) [34, 35].
Income and other socio-demographic variables
We asked participants about their approximate monthly
household income level. Less than 6000 CHF was classi-
fied as low, around 6000 CHF was classified as middle,
and more than 6000 CHF was classified as high for Swiss
households. All other answers were classified as un-
known. The Swiss Federal Statistical Office provided all
other socio-demographic variables, including age, sex,
nationality, and language region.
Statistical analyses
All statistical analyses were conducted using R version
3.4.2 [36] and SPSS version 25 [37]. We adjusted our esti-
mates to account for the stratified sampling design de-
scribed above and non-response using the R package
“survey” [38]. We used the package to specify our survey
design. The sampling probabilities were computed for
simple random sampling within strata as specified by the
sampling plan. The true population sizes for each stratum
were provided by the Swiss Federal Statistical Office. Be-
cause the percentage of missing values was limited to less
than 2% for all variables, we did not impute any values.
To describe the study participants, we calculated
weighted mean values and proportions for age, sex,
Swiss nationality, and language region as well as the
prevalence of CMDs, risky substance use, perceived need
for help, and professional mental health service
utilization (lifetime and current) by sex and Swiss na-
tionality. We compared the mental health outcomes current
suicidal ideation, lifetime suicide attempts, and mental
health-related quality of life between participants who did
and did not screen positive for one or more CMDs.
To calculate the treatment gap, we used these estimates
to determine the percentage of participants who screened
positive for CMDs who either did not perceive a need for
care or had not used professional mental health services.
We examined the association of risky alcohol and drug
use with perceived need for care and service utilization by
performing logistic regression analyses for each drug indi-
vidually, first alone and then adjusting for relevant socio-
demographic and health care service characteristics.
Results
Participant socio-demographic characteristics
We used a weighting procedure to adjust our results
to reflect the socio-demographic characteristics of the
Swiss population (Table 1). After weighting, the aver-
age age of the participants was 19.6 years, 49.5% were
female, 81.3% had Swiss nationality, and 68.3% were
from the German-speaking region, 27.1% from the
French-speaking region, and 4.7% from the Italian-
speaking region. These weighted values fairly closely
represented the socio-demographic characteristics of
the population [35].
Prevalence of CMD symptoms and risky substance use
Our study found that a quarter of youth reported symp-
toms indicating the presence of at least one of the CMDs
(Table 2). Among these disorders, the most prevalent was
depression at 17.7% followed by anxiety (13.2%) and
ADHD (8.7%). The prevalence estimates for anxiety, de-
pression, and screening positive for any of the three disor-
ders were significantly higher in women than for men; for
ADHD, the estimates were also higher, though not signifi-
cantly so. The same pattern was found among Non-Swiss
as opposed to Swiss participants (29.5% vs. 23.6% for any
of the three disorders, 11.2% vs. 8.1% for ADHD, 16.5% vs.
12.4% for anxiety, and 23.1% vs. 16.4% for depression).
Over one-third of participants reported risky alcohol
use at least monthly; risky alcohol use at least weekly
was 11.2%. Risky cannabis use was 6.2%, risky illicit drug
use was 3.8%, and risky non-prescribed prescription drug
use was 9.7%. While women reported lower weekly risky
alcohol use and risky use of cannabis and illicit drugs,
men and women did not differ in monthly risky use of
alcohol, and women reported more risky use of non-
prescribed prescription drugs. Compared with Non-
Swiss participants, Swiss participants were significantly
more likely to report both monthly and weekly risky al-
cohol use; however, risky substance use did not other-
wise significantly differ between Swiss and Non-Swiss.
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Relationship between positive CMD screening and other
mental health outcomes
Screening positive for one or more CMD was generally as-
sociated with more current suicidal ideation, lifetime sui-
cide attempts, and worse mental health-related quality of
life (Table 3). The only CMD that was not associated with
worse mental health-related quality of life than that of
those who did not screen positive for a CMD was ADHD
alone. Screening positive for depression alone was associ-
ated with worse mental health outcomes than anxiety
alone. The more comorbid positive CMD screenings, the
more current suicidal ideation and lifetime suicide at-
tempts and the worse mental health-related quality of life.
Perceived need for care, service utilization, and treatment
gap
The proportion of participants who perceived a need
for care and used mental health care services differed
by CMD and number of comorbidities (Table 4). Par-
ticipants who screened positive for ADHD alone had
the lowest perceived need and service utilization,
while participants with all three diagnoses had the
highest (comparing the two groups, one-third vs. two-
thirds perceived a need for care, a quarter vs. just
over half had ever used services, and less than 10%
vs. almost one-third were currently using services).
Among participants who screened positive for at least
one CMD, almost half did not perceive a need for
treatment, almost two-thirds had not ever utilized
professional health care services during their lifetime,
and more than four in five were not currently using
professional health care services.
As we found for the prevalence rates of CMD
symptoms, there were sex and nationality differences
in perceived need for care and service utilization.
Among those screening positive for CMDs, a higher
percentage of women tended to perceive a need for
care; however, it should be noted that the confidence
intervals for these point estimates are relatively wide
and overlapping between women and men. In gen-
eral, the same pattern was observed for service
utilization. Non-Swiss participants reported similar
levels of perceived need for care as Swiss partici-
pants with the exception of those who screened
positive for anxiety alone, anxiety and ADHD, and
depression and ADHD, who all reported less per-
ceived need for care. For anxiety alone and anxiety
and ADHD, we observed the same pattern for life-
time service utilization; however, when assessing
current service utilization, we observed the opposite
Table 1 Demographic characteristics of participants (n = 3840)
Unweighted Weighted
Mean age in years 19.6 (95% CI: 19.5–19.6) 19.6 (95% CI: 19.5–19.6)
Sex (% female) 57.7% (95% CI: 56.1–59.3) 49.5% (95% CI: 49.0–50.0)
Nationality (% Swiss) 77.1% (95% CI: 75.8–78.5) 81.3% (95% CI: 81.2–81.4)
Region (%)
German-speaking 65.4% (95% CI: 63.9–66.9) 68.3% (95% CI: 67.7–68.9)
French-speaking 28.6% (95% CI: 27.2–30.1) 27.1% (95% CI: 26.5–27.6)
Italian-speaking 6.0% (95% CI: 5.3–6.8) 4.7% (95% CI: 4.4–4.9)
Table 2 Weighted prevalence of common mental disorders and risky substance use by sex and nationality (n = 3840)
Total Male Female Swiss Non-Swiss
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
ADHD, anxiety, or depressiona,b 24.7% (23.3–26.1) 18.8% (16.9–20.8) 30.7% (28.8–32.7) 23.6% (22.1–25.2) 29.5% (26.2–32.7)
ADHD 8.7% (7.7–9.6) 7.4% (6.1–8.8) 9.9% (8.6–11.2) 8.1% (7.1–9.0) 11.2% (9.0–13.5)
Anxietya 13.2% (12.1–14.2) 9.1% (7.7–10.6) 17.3% (15.7–18.9) 12.4% (11.2–13.6) 16.5% (13.9–19.1)
Depressiona,b 17.7% (16.5–18.9) 11.5% (9.9–13.1) 23.9% (22.1–25.8) 16.4% (15.1–17.7) 23.1% (20.2–26.1)
Risky alcohol useb (at least monthly) 36.2% (34.7–37.8) 37.6% (35.2–40.0) 34.8% (32.8–36.8) 39.6% (37.8–41.4) 21.7% (18.8–24.6)
Risky alcohol usea,b (at least weekly) 11.2% (10.1–12.2) 13.0% (11.4–14.7) 9.3% (8.1–10.5) 12.3% (11.1–13.5) 6.5% (4.7–8.3)
Risky cannabis usea 6.2% (5.4–7.0) 8.5% (7.1–9.9) 3.9% (3.0–4.7) 6.5% (5.5–7.4) 5.1% (3.5–6.7)
Risky illicit drug usea 3.8% (3.2–4.4) 4.8% (3.8–5.9) 2.8% (2.0–3.5) 4.0% (3.3–4.8) 2.8% (1.6–4.0)
Risky non-prescribed prescription drug usea 9.7% (8.8–10.7) 7.7% (6.4–9.1) 11.8% (10.4–13.2) 9.8% (8.7–10.9) 9.5% (7.5–11.6)
aSignificantly different between male and female; b Significantly different between Swiss and non-Swiss
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pattern for anxiety alone (i.e., a higher percentage of
non-Swiss participants reported currently using
services).
Association of alcohol and drug use with perceived need
for care and mental health care service utilization
As opposed to participants who screened positive for a
CMD and reported risky alcohol use, those who reported
risky use of cannabis, illicit drugs, or non-prescribed pre-
scription drugs were more likely to perceive a need for
care (Table 5). After adjusting for relevant socio-
demographic and health care service characteristics, risky
alcohol and drug use were not associated with lifetime ser-
vice utilization. However, risky weekly alcohol use was as-
sociated with lower current service utilization, while risky
non-prescribed prescription drug use was associated with
higher current service utilization.
Discussion
In this nationally representative study of young adults in
Switzerland, around one-third of young women and one-
fifth of young men met the criteria for at least one of the
CMDs studied. Screening positive for at least one of the
CMDs studied was more common in non-Swiss than in
Swiss participants. Of all participants who met the criteria
for CMDs, half did not perceive a need for treatment.
Those screening positive for one or more CMDs reported
more current suicidal ideation, lifetime suicide attempts,
and lower mental health-related quality of life. Risky
weekly alcohol among young people with CMDs was asso-
ciated with lower current service utilization.
Prevalence of CMD symptoms and risky substance use
Our current prevalence estimates for anxiety, depression,
and ADHD in young Swiss adults are higher than those
found in other international epidemiological studies [39, 40].
This could be due to geographical variation and cultural dif-
ferences in the population examined and instrument used
(i.e., a structured, in-person interview assessment as in CIDI
vs. an online screening instrument). One could argue that
the high prevalence values found in our study were due to
self-report symptoms and the lack of a clinical diagnosis.
However, all of the instruments for assessing CMDs have
been used widely in clinical settings and demonstrated high
specificity compared to the gold standard (82–99.5%) [23,
25]. This means that these instruments have a high prob-
ability of correctly identifying individuals without the dis-
order. In addition, we measured other mental health
outcomes and found that those screening positive for one
or more CMDs reported more current suicidal ideation
and lifetime suicide attempts and worse mental health-
related quality of life. It is also possible that, as has been ob-
served in other countries [3, 15], the prevalence of these
CMDs could be increasing in Switzerland, and many of the
most widely referenced international prevalence studies
have been performed over a decade ago.
Our prevalence estimate for depression can be com-
pared directly with the PHQ-9 results from the Swiss
Health Survey 2012 and 2017 [41] (the PHQ-9 was one
of the only instruments on mental health covered in this
survey). Our estimate of 17.7% is significantly higher
than the estimate for 17–22 year-olds provided by the
Swiss Federal Statistical Office at 10.9% in 2012 [41].
The values from the Swiss Health Survey 2017 were
higher overall, including for the age group 15–24 at
12.3% for men and 13.9% for women [42]. Though esti-
mates of the current prevalence of anxiety are not avail-
able for young adults in Switzerland specifically,
international estimates are also lower than those found
in our study [39, 40, 43].
Table 3 Relationship between screening positive for common mental disorders and other health-related outcomes (n = 3840,
weighted analysis)
Prevalence of current suicidal
ideation
Prevalence of lifetime suicide
attempt
Mental health-related quality of
life
% (95% CI) % (95% CI) Mean (95% CI)
No diagnosis 5.1% (4.3–6.0) 2.1% (1.5–2.6) 56.6 (56.3–57.0)
ADHD alone 6.4% (1.9–10.8) 3.9% (0.0–7.4) 51.1 (48.9–53.4)
Anxiety alone 17.1% (10.1–24.2) 5.3% (1.4–9.3) 44.6 (42.7–46.6)
Depression alone 41.9% (35.6–48.1) 10.7% (6.7–14.7) 39.9 (38.3–41.5)
Anxiety and ADHD 23.4% (3.4–43.5) –b 43.4 (38.4–48.4)
Depression and ADHD 39.1% (25.9–52.3) 5.3% (0.0-11.4)a 40.6 (37.0–44.3)
Anxiety and depression 51.0% (44.6–57.5) 19.6% (14.5–24.8) 34.9 (33.5–36.4)
ADHD, anxiety, and
depression
63.2% (54.8–71.7) 28.0% (20.0–36.1) 30.7 (28.8–32.6)
Anxiety, depression, or
ADHD
38.6% (35.4–41.8) 13.0% (10.8–15.2) 39.7 (38.8–40.6)
aConfidence interval rounded to stay within possible values bno estimate
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Table 4 Weighted prevalence of perceived need for care and professional mental health service utilization for common mental
disorders and risky substance use by sex and nationality (n = 981)
Total Male Female Swiss Non-Swiss
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Perceived need (lifetime)
ADHD alone 33.7% (24.9–42.5) 30.2% (17.8–42.7) 38.1% (25.9–50.2) 33.1% (23.2–42.9) 36.8% (17.7–55.9)
Anxiety alone 38.3% (29.1–47.5) 35.9% (22.1–49.8) 40.8% (28.9–52.7) 39.9% (29.6–50.1) 30.1% (10.6–49.5)
Depression alone 51.8% (45.6–58.1) 50.4% (38.9–62.0) 52.6% (45.3–60.0) 52.3% (45.1–59.5) 50.1% (37.4–62.9)
Anxiety and ADHD 60.7% (37.8–83.5) 60.1% (17.1–100.0)a 60.9% (34.5–87.3) 62.6% (38.0–87.1) 47.0% (0.0–100.0)a
Depression and ADHD 51.8% (38.2–65.3) 41.9% (16.4–67.4) 57.2% (41.9–72.6) 57.6% (41.8–73.3) 32.9% (9.9–55.9)
Anxiety and depression 61.2% (55.0–67.4) 56.2% (42.9–69.4) 63.2% (56.3–70.1) 61.7% (54.6–68.9) 59.5% (47.1–71.9)
ADHD, anxiety, and depression 65.2% (47.0–73.4) 65.7% (50.4–81.0) 65.0% (55.4–74.6) 65.4% (55.3–75.4) 65.0% (50.9–78.1)
Anxiety, depression, or ADHD 52.0% (48.8–55.3) 46.6% (40.8–52.4) 55.5% (51.6–59.3) 52.3% (48.5–56.0) 51.3% (44.8–57.8)
Lifetime service utilization
ADHD alone 24.5% (16.5–32.5) 25.4% (13.7–37.2) 23.3% (13.0–33.6) 23.8% (14.8–32.8) 27.6% (10.2–44.9)
Anxiety alone 30.9% (22.4–39.3) 27.1% (14.3–39.8) 34.6% (23.6–45.7) 33.3% (23.8–42.9) 17.7% (1.7–33.7)
Depression alone 34.5% (28.6–40.3) 30.9% (20.2–41.6) 36.5% (29.6–43.4) 34.5% (27.7–41.2) 34.5% (22.5–46.4)
Anxiety and ADHD 33.8% (10.9–56.7) 43.6% (0.0–87.8)a 28.5% (3.3–53.7) 36.5% (11.3–61.7) 14.0% (0.0–42.7)a
Depression and ADHD 37.0% (24.1–49.9) 40.0% (14.81–65.1) 35.4% (20.8–49.9) 37.7% (22.4–53.0) 34.6% (11.3–57.8)
Anxiety and depression 45.3% (38.9–51.6) 30.8% (18.3–43.2) 50.9% (43.7–58.1) 46.3% (39.0–53.7) 41.9% (29.3–54.4)
ADHD, anxiety, and depression 53.6% (44.9–62.2) 42.0% (25.8–58.2) 59.5% (49.6–69.5) 54.2% (43.6–64.7) 52.3% (37.2–67.3)
Anxiety, depression, or ADHD 38.0% (34.8–41.1) 31.0% (25.6–36.4) 42.3% (38.6–46.1) 38.1% (34.5–41.7) 37.5% (31.2–43.9)
Current service utilization
ADHD alone 9.4% (4.1–14.8) 8.9% (1.2–16.6) 10.1% (2.9–17.3) 9.4% (3.3–15.4) 9.7% (0.0–20.3)a
Anxiety alone 11.7% (5.7–17.6) 14.0% (4.2–23.9) 9.3% (2.8–15.9) 10.5% (4.2–16.9) 17.7% (1.7–33.7)
Depression alone 15.9% (11.3–20.4) 15.7% (7.1–24.2) 16.0% (10.8–21.2) 16.6% (11.3–21.9) 13.3% (4.8–21.8)
Anxiety and ADHD 6.1% (0.0–17.6)a –b 9.3% (0.0–26.5)a 6.9% (0.0–19.9)a –b
Depression and ADHD 15.4% (6.0–24.7) 12.3% (0.0–28.4)a 17.0% (5.6–28.5) 14.2% (3.5–24.8) 19.3% (0.0–38.9)a
Anxiety and depression 18.6% (13.7–23.4) 8.6% (1.6–15.6) 22.4% (16.4–28.5) 17.2% (11.9–22.6) 23.0% (12.0–33.9)
ADHD, anxiety, and depression 30.3% (22.5–38.2) 19.6% (7.0–32.2) 35.9% (26.2–45.6) 32.5% (22.8–42.2) 25.9% (12.6–39.2)
Anxiety, depression, or ADHD 16.8% (14.5–19.2) 12.7% (8.9–16.5) 19.4% (16.4–22.5) 16.3% (13.6–19.0) 18.6% (13.5–23.8)
aConfidence interval rounded to stay within possible values bno estimate
Table 5 Factors associated with perceived need for care and service utilization among participants with common mental disorders
(n = 981, weighted analysis)
Perceived need (lifetime) Lifetime service utilization Current service utilization
OR (95% CI) aOR (95% CI)a OR (95% CI) aOR (95% CI)b OR (95% CI) aOR (95% CI) b
Risky alcohol use (at least monthly) 1.3 (1.0–1.7) 1.3 (1.0–1.7) 1.0 (0.8–1.3) 0.9 (0.6–1.2) 1.0 (0.7–1.4) 0.9 (0.6–1.3)
Risky alcohol use (at least weekly) 1.2 (0.9–1.8) 1.2 (0.8–1.8) 0.9 (0.6–1.3) 0.8 (0.5–1.2) 0.5 (0.3–0.9) 0.5 (0.3–0.8)
Risky cannabis use 1.8 (1.1–2.7) 1.9 (1.2–3.1) 1.2 (0.8–1.9) 1.0 (0.6–1.7) 1.1 (0.6–1.9) 1.0 (0.5–1.8)
Risky illicit drug use 3.4 (1.8–6.2) 3.3 (1.7–6.1) 1.4 (0.9–2.4) 1.1 (0.6–1.9) 1.0 (0.5–1.9) 0.8 (0.4–1.6)
Risky non-prescribed prescription drug use 2.2 (1.5–3.1) 2.1 (1.5–3.1) 1.8 (1.3–2.4) 1.4 (0.9–1.9) 2.6 (1.8–3.8) 2.2 (1.4–3.2)
aAdjusted for sex, nationality, language region, income, regional psychiatrist density
bAdjusted for sex, nationality, language region, income, regional psychiatrist density and perceived need for treatment
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At 8.7%, the estimate for the prevalence of ADHD in
our study was in line with findings from the National
Comorbidity Survey Replication–Adolescent Supplement
in the U.S. and several recent cohort studies that re-
ported estimates for adults at 8.1–12.2% [17–19]. In our
study, ADHD symptoms were slightly more prevalent in
women, though not significantly. This finding is sup-
ported by a recent growing body of literature that
ADHD symptoms in adulthood may have an equal gen-
der ratio [18] or that women may even be more likely to
suffer from ADHD symptoms than men [19].
As in other studies [44], we observed sex differences in
risky alcohol and drug use; however, this was not the case
for monthly risky use of alcohol. Over the last years in
Switzerland, men have reported less binge drinking, while
women’s binge-drinking behavior has increased [45]. With
more than a third of participants reporting monthly risky
use of alcohol, it is possible that this behavior has become
normalized among young Swiss adults.
We also observed differences in prevalence rates between
Swiss and non-Swiss participants, with the rates generally
higher in non-Swiss participants. These results overlapped
those from a systematic review on the mental health of im-
migrants vs. the native population that found that immi-
grants suffered more often from CMDs [46]. While illicit
drug use was similar between Swiss and non-Swiss partici-
pants, the non-Swiss participants reported lower levels of
binge drinking, which could possibly be explained by differ-
ent cultural or religious views on drinking.
Treatment gap
Our study revealed a significant treatment gap among
those who screened positive for a CMD. Given the high
prevalence values found in this study, this represents a
substantial absolute number of young adults in need of
mental health care services that do not receive them
with a correspondingly significant impact on public
health. Although awareness of mental health issues is
generally increasing in Western countries [47], the lack
of perceived need could be due to low mental health lit-
eracy about clinical symptoms and the inability to seek
help, which means that mental health disorders are still
underdiagnosed and undertreated.
International studies have estimated the treatment gap at
50% or higher [8]; for example, the European Study of the
Epidemiology of Mental Disorders (ESEMeD) found that
48% of people with mood, anxiety and substance use disor-
ders severe enough to significantly interfere with everyday
life received any formal healthcare [9]. In our study, we
found that 38.0% (95% CI: 34.8–41.1%) of young adults with
symptoms indicating current anxiety, depression, or ADHD
had ever accessed care; this was close to the estimate of 35–
37% found in the Swiss Health Survey 2012 [14]. The service
utilization estimates from our survey are somewhat
comparable to 12-month utilization rates of health care ser-
vices for any mental disorder in several other high-income
countries (between 23.9 and 62.1% for moderate to severe
mental disorders) [48] at somewhere between 16.8% of par-
ticipants with any of the three disorders currently using ser-
vices and 38.0% who had ever used services.
Frequent risky alcohol use associated with less service
utilization
In line with previous studies [49, 50], we found that
young adults with mental disorders who use alcohol are
not more likely to perceive a need for professional men-
tal health services, but are less likely to be currently
using them. This could indicate a tendency to self-
medicate in the absence of professional health care ser-
vices since alcohol is a depressant that can temporarily
relieve unpleasant symptoms of CMDs [49, 50]. How-
ever, while this practice can be effective at alleviating
symptoms in the short-term, it is associated with risks in
the long run [50]. In contrast, participants with mental
disorders who use non-prescribed prescription drugs
were more likely to currently use service. One possible
explanation for this finding is that the participants with
a mental disorder that used non-prescribed prescription
drugs in our study were more likely to have depression
and/or anxiety than ADHD, and the participants with
these disorders tended to use services more than the
participants with ADHD alone.
Strengths and limitations
Our study was the first mental health survey of young
adults across Switzerland. A major strength of our study
was surveying a nationally representative sample obtained
directly from the Federal Statistical Office. Our study was
also subject to some limitations. First, our survey was con-
ducted online instead of in person, and the instruments
we used measured self-reported symptoms of mental dis-
orders. Thus, although it was possible to grade partici-
pants’ endorsement of symptoms and classify them by
disorder and severity using validated questionnaires with
high sensitivity and specificity, participants lacked a clin-
ical diagnosis. In addition, these self-reported symptoms
may not reflect the impairment or level of functioning.
However, we measured other mental health outcomes and
found that screening positive for one or more CMDs was
associated with worse mental health. Another limitation
of our study was that measurement of mental health ser-
vice availability was limited to psychiatrist density and did
not account for the availability of other mental health pro-
fessionals. Our study could also be subject to participation
bias since those sampled who could not complete the sur-
vey in German, French or Italian are not represented in
our study. Finally, we cannot rule out the possibility that
the high prevalence found in our study was in part due to
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another source of participation bias, i.e., the fact that
young adults with symptoms were more likely to partici-
pate in our study.
Implications for practice and research
Because only around half of the people with a CMD re-
ported lifetime perceived need for mental health care
services, the first step in helping young adults with men-
tal disorders to reach appropriate mental health care will
involve interventions that increase knowledge and
awareness about symptoms that could require profes-
sional mental health treatment. To uncover additional
barriers to accessing care, we conducted some prelimin-
ary analyses (results not shown) and found that the most
frequent major barrier was “wanting to solve the prob-
lem on [one’s] own.” It thus appears that the most com-
mon barriers to care in young Swiss adults reflect the
same barriers found in other studies, namely lack of per-
ceived need and the preference to manage the problem
oneself [51]. To address the large treatment gap beyond
this lack of perceived need, further research is needed to
gain a detailed understanding of the barriers to care fa-
cing subgroups of young adults so that interventions can
be tailored to address these specific barriers. Examples
of such interventions include improving screening in pri-
mary health care, strengthening mental health service in-
frastructure, and disseminating psychological and mind-
body therapies and self-care interventions [52].
Although we found that monthly binge drinking was wide-
spread among young Swiss adults, those who binge drink
more frequently could represent a specific group to be tar-
geted by interventions to improve access to care since young
adults with a CMD who reported risky weekly use of alcohol
were less likely to be currently using services. These young
adults may be unaware of the need to seek professional men-
tal health treatment due to the fact that drinking alleviates
their symptoms temporarily. If young adults could better
recognize their own need and better access appropriate treat-
ment, they might be less likely to use alcohol instead of util-
izing mental health care services.
Conclusions
The current prevalence of anxiety, depression, and
ADHD symptoms in young Swiss adults is higher than
many international estimates; as in other Western coun-
tries, the prevalence for these CMDs may be increasing.
We should thus continue to observe this population and
compare these results with other studies. Young Swiss
adults’ low recognition of need and service utilization
should be addressed through interventions to help indi-
viduals recognize moderate to severe symptoms in them-
selves and overcome barriers to reaching care. Young
people with CMDs who frequently binge drink could
particularly benefit from such interventions.
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